Tuberculosis drug discovery: challenges and new horizons
This article was originally published here
J Med Chem. 2022 May 25. doi: 10.1021/acs.jmedchem.2c00227. Online ahead of print.
Over the past 2,000 years, tuberculosis (TB) has claimed more lives than any other infectious disease. In 2020 alone, tuberculosis was responsible for 1.5 million deaths worldwide, comparable to the 1.8 million deaths caused by COVID-19. The World Health Organization has stated that new tuberculosis drugs must be developed to end this pandemic. After decades of neglect in this field, an era of renaissance in tuberculosis drug discovery has arrived, during which many new candidates have entered clinical trials. However, while hundreds of molecules are reported each year as promising anti-TB agents, very few successfully progress to clinical development. With this in mind, we critically review anti-tuberculosis compounds published over the past 6 years that demonstrate good live effectiveness against Mycobacterium tuberculosis. Additionally, we highlight key challenges and strategies for developing novel TB drugs and the current global pipeline of drug candidates in clinical studies to foment new research insights.